Key Points
- CEO Amit Gupta sold 6,676 Cardlytics shares at an average price of $4.03, generating $26,904.28. The sale reduced his ownership by 5.06% to 125,389 shares.
- Cardlytics shares opened at $4.12 and remain near their 12-month low of $3.49, with a market capitalization of approximately $23.94 million. The company reported a quarterly loss of $1.50 per share, though it beat analysts’ loss estimate of $2.30.
- Analysts maintain a bearish outlook, with a consensus rating of “Sell” from one Hold and two Sell ratings, despite a $10.00 consensus price target. Institutional investors own approximately 68.1% of the company.
Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CEO Amit Gupta sold 6,676 shares of Cardlytics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $4.03, for a total value of $26,904.28. Following the completion of the transaction, the chief executive officer owned 125,389 shares of the company's stock, valued at $505,317.67. This trade represents a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Amit Gupta also recently made the following trade(s):
- On Monday, August 17th, Amit Gupta sold 6,785 shares of Cardlytics stock. The shares were sold at an average price of $3.97, for a total value of $26,936.45.
- On Monday, July 6th, Amit Gupta sold 9,640 shares of Cardlytics stock. The shares were sold at an average price of $4.39, for a total transaction of $42,319.60.
- On Thursday, July 2nd, Amit Gupta sold 6,498 shares of Cardlytics stock. The shares were sold at an average price of $4.39, for a total transaction of $28,526.22.
Cardlytics Trading Up 1.7%
Shares of Cardlytics stock opened at $4.12 on Wednesday. The stock has a market capitalization of $23.94 million, a price-to-earnings ratio of -0.22 and a beta of 0.62. The business's 50 day simple moving average is $4.36 and its 200-day simple moving average is $6.99. Cardlytics, Inc. has a twelve month low of $3.49 and a twelve month high of $32.80.
Cardlytics (NASDAQ:CDLX - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.30) by $0.80. Cardlytics had a negative return on equity of 956.56% and a negative net margin of 55.92%.The company had revenue of $36.88 million for the quarter, compared to analysts' expectations of $37.00 million. Sell-side analysts predict that Cardlytics, Inc. will post -3.89 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on CDLX. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Cardlytics in a research note on Wednesday, July 8th. Lake Street Capital set a $10.00 price target on Cardlytics in a research note on Friday, May 8th. Needham & Company LLC reissued a "hold" rating on shares of Cardlytics in a research note on Thursday, June 18th. Finally, Wall Street Zen upgraded Cardlytics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Sell" and a consensus price target of $10.00.
Read Our Latest Analysis on CDLX
Hedge Funds Weigh In On Cardlytics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its stake in Cardlytics by 262.7% in the 3rd quarter. Bank of America Corp DE now owns 1,632,786 shares of the company's stock valued at $3,968,000 after buying an additional 1,182,593 shares during the last quarter. Geode Capital Management LLC raised its holdings in Cardlytics by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 654,472 shares of the company's stock valued at $753,000 after acquiring an additional 20,908 shares in the last quarter. UBS Group AG lifted its position in Cardlytics by 112.5% in the third quarter. UBS Group AG now owns 458,066 shares of the company's stock worth $1,113,000 after purchasing an additional 242,536 shares during the period. Invesco Ltd. lifted its holdings in shares of Cardlytics by 38.1% during the 4th quarter. Invesco Ltd. now owns 170,122 shares of the company's stock worth $196,000 after acquiring an additional 46,973 shares during the period. Finally, Jane Street Group LLC lifted its stake in Cardlytics by 263.0% during the second quarter. Jane Street Group LLC now owns 162,427 shares of the company's stock worth $267,000 after purchasing an additional 117,687 shares during the period. Institutional investors and hedge funds own 68.10% of the company's stock.
Cardlytics Company Profile
(
Get Free Report)
Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers' online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.
At the core of Cardlytics' offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
